Yes, you can survive liver cancer, and tens of thousands of people do. But survival depends heavily on when the cancer is found and how well your liver is functioning overall. When liver cancer is caught early and hasn’t spread beyond the liver, about 38% of people are alive five years later. When it has spread to distant organs, that number drops to 3.5%. The gap between those two figures tells you almost everything about why early detection matters so much with this disease.
Survival Rates by Stage
The most reliable survival data for liver cancer comes from the National Cancer Institute’s SEER database, which tracks outcomes across the United States. These are five-year relative survival rates, meaning they compare people with liver cancer to the general population of the same age.
- Localized (cancer confined to the liver): 37.6% five-year survival. About 45% of liver cancers are diagnosed at this stage.
- Regional (spread to nearby lymph nodes or tissues): 13.2% five-year survival. Around 24% of cases fall here.
- Distant (cancer has spread to other organs): 3.5% five-year survival. About 21% of diagnoses are at this stage.
These numbers reflect cases diagnosed between 2015 and 2021, so they include many patients treated with older approaches. Newer treatments, particularly immunotherapy combinations introduced in the last few years, are improving outcomes for advanced cases. It’s also worth noting that these are averages across all patients, including those with severely damaged livers from cirrhosis. Individual outcomes can be significantly better depending on your specific circumstances.
Why Liver Health Matters as Much as Cancer Stage
Liver cancer is unusual because most people who develop it already have a damaged liver, usually from cirrhosis caused by hepatitis B, hepatitis C, alcohol use, or fatty liver disease. This creates a two-front problem: the cancer itself and the failing organ it grows in. Your liver’s ability to function, measured by doctors using scoring systems that assess things like blood clotting, fluid retention, and toxin processing, directly shapes which treatments you can tolerate and how long you’re likely to survive.
Someone with a well-functioning liver and a small tumor has a fundamentally different outlook than someone with the same tumor but a liver that’s barely keeping up. In studies of patients receiving systemic therapy, those with better liver function had a median survival of about 20 months, while those with more compromised livers did significantly worse. Vascular involvement (when the tumor grows into blood vessels within the liver) and the degree of cirrhosis are both tied to shorter survival times.
Surgery and Transplant: The Best Odds
For people whose cancer is caught early enough, surgery offers the strongest chance of long-term survival. There are two main surgical paths: removing the tumor (resection) or replacing the entire liver (transplant).
Liver transplant produces the best overall results because it eliminates both the cancer and the underlying diseased liver. A large analysis comparing the two approaches found that transplant patients had roughly 35% better overall survival and more than double the disease-free survival at five years compared to resection patients. For people who meet what are known as the Milan criteria, a single tumor no larger than 5 centimeters or two to three tumors each 3 centimeters or smaller, the five-year survival rate after transplant is about 74%, and 62% are still alive at 10 years. Cancer recurrence within 10 years happens in about 13% of these patients.
Even people whose tumors initially exceed those size limits can sometimes benefit. If treatment shrinks the cancer enough to qualify for transplant (a process called downstaging), about 52% survive 10 years, with a recurrence rate of 21%. These are meaningful, long-term outcomes.
The catch is organ availability. Wait times for a donor liver can be long, and the cancer may progress during that wait. Resection is more immediately accessible and still produces good results: one study found that about 16% of patients who had liver resection survived 10 years or more.
Recurrence After Surgery Is Common
One of the hardest realities of liver cancer is how often it comes back. Among patients who undergo surgical resection with the goal of a complete cure, the five-year recurrence rate reaches about 70%. That’s a difficult number, but context matters. Recurrence doesn’t always mean the end of treatment options.
Where the cancer returns makes a big difference. When it recurs only within the liver, five-year survival after that recurrence is around 43%. When it returns in distant organs, five-year survival drops to about 12.5%. Timing also matters: cancer that comes back within the first year after surgery carries a worse prognosis than later recurrence. This is why follow-up monitoring after surgery is intensive, with regular imaging and blood tests, so any return can be caught and treated as early as possible.
Ablation for Small Tumors
Not everyone is a candidate for major surgery. For people with small liver tumors who can’t undergo resection or transplant, heat-based ablation treatments can destroy tumors directly. These procedures use a needle-like probe inserted through the skin to deliver heat (either radiofrequency energy or microwave energy) to the tumor.
Ablation works best on tumors smaller than about 4 centimeters. For small, solitary tumors in that range, studies report five-year survival rates around 40%, with a median survival of nearly five years. That approaches the results of surgical resection in some cases, making ablation a viable option for people whose overall health or liver function rules out a bigger operation.
Treatment for Advanced Liver Cancer
When liver cancer has spread beyond the liver or can’t be treated with surgery or ablation, systemic therapy becomes the main approach. The standard first-line treatment now combines immunotherapy with a drug that cuts off blood supply to tumors. This combination has changed the landscape for advanced liver cancer over the past several years.
In real-world practice (not just carefully selected clinical trial patients), this regimen produces a median overall survival of about 14.7 months. At one year, 57% of patients are still alive; at two years, about 41% are. For patients in better overall health with well-functioning livers, the median survival stretches to about 20.6 months. These numbers may not sound large, but they represent a substantial improvement over what was available a decade ago, when median survival for advanced liver cancer was closer to 6 to 8 months.
Early Detection Changes the Equation
Because survival rates are so much higher when liver cancer is found early, screening in high-risk populations has a real, measurable impact. Randomized trials have shown that regular surveillance with ultrasound and blood tests in people with chronic hepatitis B reduces liver cancer mortality by 37%. That’s not a small effect. It means more cancers found at the localized stage, more people eligible for curative treatments, and more long-term survivors.
If you have cirrhosis from any cause, chronic hepatitis B or C, or other known risk factors, routine screening every six months is the standard recommendation. The test itself is simple: an abdominal ultrasound, sometimes paired with a blood test that measures a protein produced by liver tumors. Finding a tumor at 2 centimeters rather than 8 centimeters is often the difference between a cure and palliative care.
What Shapes Your Individual Outlook
Population statistics give you a starting framework, but several factors push individual outcomes higher or lower. Tumor size and number matter, but so does whether the cancer has grown into blood vessels within the liver, which makes it harder to treat surgically and more likely to spread. Your underlying liver function is equally important, sometimes more so. A person with a small tumor but severe cirrhosis may have fewer options than someone with a slightly larger tumor in an otherwise healthy liver.
Age, overall fitness, and the specific biology of the tumor all play roles too. Response to initial treatment is one of the strongest predictors: people whose tumors shrink or stabilize with first-line therapy tend to have significantly longer survival than those whose cancers progress through treatment. The 10-year survival data, 62% for transplant patients within Milan criteria, 16% for resection patients overall, shows that long-term survival is not just possible but a real outcome for a meaningful number of people.